Regulation of susceptibility and severity of inflammatory diseases of the central nervous system by novel innate immune signaling pathways in human myeloid cells
Project Number2I01BX000467-09A1
Contact PI/Project LeaderCARRITHERS, MICHAEL D
Awardee OrganizationJESSE BROWN VA MEDICAL CENTER
Description
Abstract Text
Individual variation in inflammatory responses regulates onset and severity of multiple sclerosis (MS) and other
types of brain injury. Initiation, amplification, and resolution of these inflammatory responses occur in part
through innate immune signaling mediated by macrophages and related immune cells. This laboratory has
discovered novel innate immune signaling pathways in human macrophages that are regulated by intracellular
splice variants of voltage-gated sodium channels. These channels regulate pattern recognition of dsRNA,
intracellular signaling, vesicular trafficking, and transcription of anti-viral genes. In a mouse model of MS,
expression of one of these channels, human macrophage SCN5A, in mouse macrophages reduced disease
severity and enhanced tissue repair. Recently published work demonstrates that a newly discovered channel
variant, human macrophage SCN10A, acts in a synergistic manner with SCN5A to regulate RNA processing of
a transcript that encodes a DNA repair protein, PPP1R10. New preliminary data demonstrate individual
variation in regulation of PPP1R10 expression. New data also reveal that SCN10A localizes to mitochondria
during cellular injury and regulates ATP production. The objective of this revised proposal is to characterize
these innate immune signaling mechanisms in human cells and an animal model. The central hypothesis is
that human macrophage SCN10A and SCN5A prevent cell and tissue injury through enhancement of DNA
repair and maintenance of cellular bioenergetics. This hypothesis will be assessed in three aims: 1) Analyze
how human macrophage channel variants regulate PPP1R10 protein expression, 2) Determine how the human
macrophage channel variants regulate mitochondrial function, and 3) Characterize how macrophage SN10A
and SCN5A prevent tissue injury. For Aim 1, the proposed model is that endogenous signals of cellular injury
activate human macrophage SCN10A and SCN5A to initiate a calcium-dependent nuclear signaling pathway
that regulates expression of the DNA repair protein PPP1R10. It is hypothesized that individual variation in this
pathway increases the risk of tissue injury in inflammatory diseases such as MS. For Aim 2, it is proposed that
human macrophage SCN10A localizes to mitochondria during cellular injury to transiently increase
mitochondrial ATP production. It is also hypothesized that SCN10A and SCN5A regulate mitophagy, a cellular
protective mechanism. For Aim 3, it is postulated that macrophages that express human variants of SCN5A
and SCN10A prevent tissue injury in inflammatory lesions through enhancement of DNA repair and
maintenance of bioenergetics. These hypotheses will be tested using multidisciplinary approaches in primary
cultures of human macrophages; macrophages, microglia, and neurons derived from human induced-
pluripotent stem cells; and in the mouse model of multiple sclerosis, experimental autoimmune
encephalomyelitis. The expectations are that we will identify novel regulatory mechanisms of bioenergetics and
tissue repair that are relevant to MS and related diseases. The long-term goals are to develop new biomarkers
of disease susceptibility and severity and identify novel therapeutic strategies that prevent and reduce long-
term disability of Veterans with MS.
Public Health Relevance Statement
Multiple sclerosis (MS) is an autoimmune, inflammatory disease that is a common cause of disability in young
adults. The VA provides care for approximately 16,000 MS patients a year, and 6,000 are service connected
for this condition. The cost of caring for Veterans with MS is very high. Medications used to treat MS are only
partially effective and very costly. The goals of our research are to identify ways to prevent tissue injury and
enhance recovery in patients with MS and other inflammatory diseases. Using human immune cells and a
mouse model of MS, we have identified novel signaling pathways that maintain cell survival during injury,
decrease inflammation, and promote clinical recovery. The goals of this proposal are to examine how these
signaling pathways work in human immune cells and how they prevent injury to neurons in the brain and spinal
cord. These studies are also relevant to other types of brain diseases that are associated with inflammation
such as traumatic brain injury, stroke, and Alzheimer's disease.
No Sub Projects information available for 2I01BX000467-09A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2I01BX000467-09A1
Patents
No Patents information available for 2I01BX000467-09A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2I01BX000467-09A1
Clinical Studies
No Clinical Studies information available for 2I01BX000467-09A1
News and More
Related News Releases
No news release information available for 2I01BX000467-09A1
History
No Historical information available for 2I01BX000467-09A1
Similar Projects
No Similar Projects information available for 2I01BX000467-09A1